908 Devices (NASDAQ:MASS) Price Target Lowered to $12.00 at Leerink Partners

908 Devices (NASDAQ:MASS) had its target price decreased by analysts at Leerink Partners from $15.00 to $12.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Leerink Partners’ target price indicates a potential upside of 253.98% from the stock’s previous close.

908 Devices Stock Down 4.0 %

Shares of NASDAQ:MASS traded down $0.14 during trading on Thursday, hitting $3.39. 29,565 shares of the company were exchanged, compared to its average volume of 197,146. 908 Devices has a 1-year low of $3.24 and a 1-year high of $12.51. The company has a market capitalization of $116.90 million, a P/E ratio of -3.17 and a beta of 0.97. The business’s 50 day moving average is $3.76 and its 200-day moving average is $5.08.

908 Devices (NASDAQ:MASS) last issued its earnings results on Tuesday, August 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.02. The business had revenue of $14.05 million during the quarter, compared to analysts’ expectations of $13.69 million. 908 Devices had a negative return on equity of 22.47% and a negative net margin of 72.10%. As a group, sell-side analysts anticipate that 908 Devices will post -1.21 earnings per share for the current year.

Institutional Investors Weigh In On 908 Devices

A number of institutional investors have recently added to or reduced their stakes in MASS. State Board of Administration of Florida Retirement System bought a new stake in shares of 908 Devices in the first quarter worth $80,000. Vanguard Group Inc. grew its position in shares of 908 Devices by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 1,751,102 shares of the company’s stock valued at $13,221,000 after buying an additional 6,772 shares during the last quarter. AWM Investment Company Inc. increased its stake in shares of 908 Devices by 2.3% in the first quarter. AWM Investment Company Inc. now owns 668,526 shares of the company’s stock valued at $5,047,000 after buying an additional 15,058 shares during the period. GAMMA Investing LLC acquired a new stake in shares of 908 Devices in the second quarter valued at about $48,000. Finally, Bank of New York Mellon Corp raised its position in shares of 908 Devices by 6.4% during the second quarter. Bank of New York Mellon Corp now owns 69,550 shares of the company’s stock worth $358,000 after acquiring an additional 4,212 shares during the last quarter. 88.06% of the stock is owned by institutional investors.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.